天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Specialty drugs>Ophthalmic drugs>Verteporfin
Verteporfin
  • Verteporfin

Verteporfin NEW

Price $34 $47 $77
Package 1mg 2mg 5mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: Verteporfin CAS No.: 129497-78-5
Purity: 99.82% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameVerteporfin
DescriptionVerteporfin (BPD-MA) is a YAP inhibitor that inhibits YAP-TEAD interactions. Verteporfin is also a photosensitizer used in photodynamic therapy. Verteporfin also induces apoptosis and inhibits autophagy.
Cell ResearchVerteporfin is dissolved in DMSO. PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and dasatinib (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and dasatinib, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects.
Kinase AssayCells (5 × 103) are plated in 96 well plates. Cells are treated the next day for 24 to 48 hours and then assessed for caspase-3 activity by Caspase-Glo-3/7 Assay, as per manufacturer's instructions and a luminescence plate reader.
In vitroVerteporfin metabolizes into a less active form within the body and is rapidly cleared, primarily excreted via feces and to a lesser extent through urine. Its therapy is effective and selectively prevents fluorescein dye leakage from choroidal neovascularization (CNV) induced in experimental monkeys. Verteporfin quickly accumulates in the choroidal vasculature, retinal pigment epithelium (RPE), and photoreceptors of established rabbit eyes. Upon intravenous injection in mice, peak tissue levels of Verteporfin are reached within 3 hours, followed by a rapid decline within 24 hours.
In vivoVerteporfin forms a complex with LDL, which may be taken up by proliferating cells (e.g., neovascular endothelial cells) through LDL receptors or endocytosis. The therapy with Verteporfin achieves complete vascular occlusion through thrombosis in the vascular channels following selective endothelial damage. As shown by optical and electron microscopy, Verteporfin therapy selectively induces occlusion in regenerating and detached choroidal capillaries, without altering the overlying photoreceptors or ganglion cells. Verteporfin rapidly exhibits apoptotic changes in conjunction with light, as demonstrated by the activation of caspase-3 and caspase-9 and the cleavage of PARP in HL-60 cells, changes that are inhibited by the broad-spectrum caspase inhibitor ZVAD.fmk.
Storagekeep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationEthanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 93 mg/mL (129.4 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
KeywordsCL318952 | inhibit | Yes-associated protein | Verteporfin | CL-318952 | Autophagy | Apoptosis | Inhibitor | YAP
Inhibitors RelatedStavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Tributyrin | Paeonol | Naringin
Related Compound LibrariesBioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$1.10/1g
VIP4Y
Dideu Industries Group Limited
2021-08-16
$1.10/1g
VIP4Y
Shaanxi Dideu Medichem Co. Ltd
2021-05-25
$1.00/1KG
VIP7Y
Career Henan Chemical Co
2019-05-23
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY